11 Appendix 426 11.1 Bibliography 426 11.2 Abbreviations 452 11.3 Methodology 459 11.4 Forecasting Methodology 459 11.4.1 Diagnosed RA Patients 459 11.4.2 Percentage of Drug-Treated Patients 460 11.4.3 Drugs Included in Each Therapeutic Class 460 11.4.4 Launch and Patent Expiry Dates 461 11.4.5 General Pricing Assumptions 462 11.4.6 Individual Drug Assumptions 464 11.4.7 Generic and Biosimilar Erosion 476
Browse Complete Summary Click Here @ http :// www . radiantinsights . com / research / pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023
11.4.8 Pricing of Pipeline Agents 476 11.5 Primary Research - KOLs Interviewed for This Report 479 11.6 Primary Research - Prescriber Survey 481 11.7 About the Authors 481 11.7.1 Analyst 481 11.7.2 Reviewer 482 11.7.3 Therapy Area Director 482 11.7.4 Epidemiologist 483 11.7.5 Global Head of Healthcare 484 11.8 About GlobalData 485 11.9 Disclaimer 485